MaxCyte, Inc. Research and Development Expense
MaxCyte, Inc. (MXCT) reported Research and Development Expense of $4.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- MaxCyte, Inc. research and development expense for the quarter ending 2026-06-30 was $4.25M, a 32.16% decline year-over-year.
- MaxCyte, Inc. research and development expense for the quarter ending 2026-03-31 was $3.86M, a 34.66% decline year-over-year.
- MaxCyte, Inc. research and development expense for the quarter ending 2025-12-31 was $3.33M, a 27.72% decline year-over-year.
- MaxCyte, Inc. research and development expense for the quarter ending 2025-09-30 was $5.32M, a 0.00% change year-over-year.
- MaxCyte, Inc. research and development expense for fiscal 2025 was $20.82M, a 6.32% decline from fiscal 2024.
- MaxCyte, Inc. research and development expense for fiscal 2024 was $22.23M, a 6.68% decline from fiscal 2023.
- MaxCyte, Inc. research and development expense for fiscal 2023 was $23.82M, a 22.05% increase from fiscal 2022.
- MaxCyte, Inc. research and development expense for fiscal 2022 was $19.51M, a 26.65% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.25M 10-Q · filed 2026-08-13 | $8.11M 10-Q · filed 2026-08-13 | $11.45M derived: sum of 3 quarters · filed 2026-08-13 | $16.76M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $3.86M 10-Q · filed 2026-05-13 | $7.19M derived: sum of 2 quarters · filed 2026-05-13 | $12.51M derived: sum of 3 quarters · filed 2026-05-13 | $18.78M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $8.65M derived: sum of 2 quarters · filed 2026-03-25 | $14.92M derived: sum of 3 quarters · filed 2026-08-13 | $20.82M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $5.32M 10-Q · filed 2025-11-13 | $11.59M derived: sum of 2 quarters · filed 2026-08-13 | $17.49M 10-Q · filed 2025-11-13 | $22.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $6.27M 10-Q · filed 2026-08-13 | $12.17M 10-Q · filed 2026-08-13 | $16.79M derived: sum of 3 quarters · filed 2026-08-13 | $22.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $5.90M 10-Q · filed 2026-05-13 | $10.52M derived: sum of 2 quarters · filed 2026-05-13 | $15.83M derived: sum of 3 quarters · filed 2026-05-13 | $21.45M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $9.93M derived: sum of 2 quarters · filed 2026-03-25 | $15.55M derived: sum of 3 quarters · filed 2026-03-25 | $22.23M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $5.32M 10-Q · filed 2025-11-13 | $10.94M derived: sum of 2 quarters · filed 2025-11-13 | $17.61M 10-Q · filed 2025-11-13 | $23.45M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $5.62M 10-Q · filed 2025-08-06 | $12.30M 10-Q · filed 2025-08-06 | $18.14M derived: sum of 3 quarters · filed 2025-08-06 | $24.40M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $6.68M 10-Q · filed 2025-05-08 | $12.52M derived: sum of 2 quarters · filed 2025-05-08 | $18.78M derived: sum of 3 quarters · filed 2025-05-08 | $24.45M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $12.11M derived: sum of 2 quarters · filed 2025-03-11 | $17.77M derived: sum of 3 quarters · filed 2025-03-11 | $23.82M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $6.26M 10-Q · filed 2024-11-06 | $6.26M 10-Q · filed 2023-11-08 | $11.93M derived: sum of 2 quarters · filed 2024-11-06 | $17.98M 10-Q · filed 2024-11-06 | $17.97M 10-Q · filed 2023-11-08 | $23.70M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $5.66M 10-Q · filed 2024-08-06 | $5.66M 10-Q · filed 2023-08-09 | $11.71M 10-Q · filed 2024-08-06 | $11.71M 10-Q · filed 2023-08-09 | $17.44M derived: sum of 3 quarters · filed 2024-08-06 | $22.76M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $6.05M 10-Q · filed 2024-05-07 | $6.05M 10-Q · filed 2023-05-10 | $11.77M derived: sum of 2 quarters · filed 2024-05-07 | $17.10M derived: sum of 3 quarters · filed 2024-05-07 | $21.80M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $5.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $11.05M derived: sum of 2 quarters · filed 2024-03-12 | $15.75M derived: sum of 3 quarters · filed 2024-03-12 | $19.51M 10-K · filed 2024-03-12 | $19.51M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $5.33M 10-Q · filed 2023-11-08 | $10.02M derived: sum of 2 quarters · filed 2023-11-08 | $13.79M 10-Q · filed 2023-11-08 | $17.17M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $4.70M 10-Q · filed 2023-08-09 | $8.46M 10-Q · filed 2023-08-09 | $11.84M derived: sum of 3 quarters · filed 2023-08-09 | $14.59M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $3.77M 10-Q · filed 2023-05-10 | $7.15M derived: sum of 2 quarters · filed 2023-05-10 | $9.89M derived: sum of 3 quarters · filed 2023-05-10 | $13.10M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $6.13M derived: sum of 2 quarters · filed 2023-03-15 | $9.33M derived: sum of 3 quarters · filed 2023-03-15 | $15.41M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $2.75M 10-Q · filed 2022-11-09 | $2.77M 10-Q · filed 2021-11-10 | $5.95M derived: sum of 2 quarters · filed 2022-11-09 | $12.03M 10-Q · filed 2022-11-09 | $12.06M 10-Q · filed 2021-11-10 | $16.91M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $3.20M 10-Q · filed 2022-08-10 | $3.21M 10-Q · filed 2021-09-13 | $9.28M 10-Q · filed 2022-08-10 | $9.28M 10-Q · filed 2021-09-13 | $14.16M derived: sum of 3 quarters · filed 2022-08-10 | $18.68M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $6.08M 10-Q · filed 2022-05-09 | $10.96M derived: sum of 2 quarters · filed 2022-05-09 | $15.48M derived: sum of 3 quarters · filed 2022-05-09 | $19.57M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $9.40M derived: sum of 2 quarters · filed 2022-03-22 | $13.49M derived: sum of 3 quarters · filed 2022-03-22 | $17.73M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $4.52M 10-Q · filed 2021-11-10 | $8.61M derived: sum of 2 quarters · filed 2021-11-10 | $12.85M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $4.09M 10-Q · filed 2021-09-13 | $8.34M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $17.59M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |